Recent Updates
Recently added Catalysts

Upcoming Catalyst

Drug Pipeline Intelligence

Clinical Trial Results

Inside Trades

Options Data

News Section

Hedge Funds

Ownership Trends

Competitive Position

Arcutis Biotherapeutics, Inc.

35 indications, side-by-side phase, drug & LoA

$23.23

+0.43 (+1.89%)

B 79Pipeline Score Undervalued Pharma · Commercial
Market Cap
2.60 B
EPS
-0.02
P/E Ratio
-1,111.76 $
Value Trade
22.59 M
SEC Financials
Q1 2026

  • Dilution Risk

    5%

  • Revenue

    105.40 M

  • R&D Expenses

    30.63 M

  • Operating CF

    2.24 M

  • Total Assets

    460.00 M

  • Total Liabilities

    270.36 M

  • Equity

    189.65 M

  • D/E Ratio

    12,345

-1.28 %
Week
-11.61 %
1 Month
-24.8 %
3 Month
-23.17 %
6 Month
-17.91 %
5 Year
-9.5 %
All Time
Cash Data
Profitable

  • Cash Position

    224.00 M

  • Monthly Burn

    -

  • Runway

    12,345 mo

  • Burn Trend

    Decelerating

  • SEC Filing

    May 6, 2026
Overview
Volume
1.41 M
52 Week Range
12.72 - 31.77
% held by Insiders
11.72 %
% held by Institutions
98.41 %
Enterprise Value
2.49 B
Total Shares
122.44 M
Short %
14.84 %
Float Shares
109.34 M
Company Description
HQ: 3027 TOWNSGATE ROAD, WESTLAKE ...
Founded:2016
Employees:354
https://www.arcutis.com

locked

Upcoming Catalyst
Catalyst Drug/Treatment Stage Probability of Approval Description Drug Type Therapeutic Area Source
PDUFA Date example
PDUFA
—
Small Molecules
Dermatologic System
PDUFA
—
Small Molecules
Dermatologic System
PDUFA
—
Small Molecules
Dermatologic System
Unlock Upcoming Catalyst data
Drug Pipeline Intelligence
B79
Pipeline Score
$16.0B
Pipeline Value
Undervalued
Valuation Signal
14
Drugs Scored
6.1x
rNPV / MCap
Top 97%
Small Cap
(rank 28 of 905)
Percentile Rank
Arcutis Biotherapeutics, Inc. holds a solid B-grade pipeline (79/100), with $24.6B risk-adjusted pipeline value, led by Roflumilast 0.3% in Chronic Plaque Psoriasis (Phase 3), across $185B in total addressable markets.
Showing 1 of 1 assets
DrugIndicationPhaseNCT IDPTRSrNPVStatusEnrollmentVelocityDesignCompletionML SignalLast Change
Roflumilast
Small molecule		Atopic Dermatitis EczemaPhase 3NCT0477360064% $5.0B COMPLETED 683 - -Sep 29, 2022 -Oct 4, 2024
Unlock Drug Pipeline Intelligence
ARQT Clinical Trial Results & History
Drug Name Indications Phase Date Trial Results Summary Title Source
ZORYVE
seborrheic dermatitis,atopic dermatitis,plaque psoriasis
Phase 3
2025-09-17
ZORYVE
seborrheic dermatitis,atopic dermatitis,plaque psoriasis
Phase 3
2025-09-17
ZORYVE
seborrheic dermatitis,atopic dermatitis,plaque psoriasis
Phase 3
2025-09-17
Unlock Clinical Trial Results data
Inside Trades
TREND
CORPORATE INSIDERS BOUGHT SHARES WORTH 1.8M IN THE LAST 3 MONTHS
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Unlock Inside Trades data
Show Data
Hedge Funds
TREND
HEDGE FUNDS INCREASED HOLDINGS BY 200.0K SHARES IN THE LAST QUARTER
Shares Held
2040.00B1530.00B1020.00B510.00B0
Q3
2024
Q4
2024
Q1
2025
Q2
2025
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Fund Count
60%
Share Volume
25%
Conviction
15%
Hedge Funds invested in ARQT
HedgeFund Name
( 3 )
% of Portfolio Current MV
-
Shares Owned
-
Activity
Avg Price $0

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K
Unlock Hedge Funds table data
Arcutis Biotherapeutics, Inc. (ARQT) Analyst Ratings & Price Targets
Symbol
Firm
Rating
Action
Price Target
Upside
date
ARQT
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
ARQT
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
ARQT
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
Unlock Biotech Analyst Ratings data
ARQT Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
Unlock Price Target Trend
ARQT Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
ARQT Option Chain Statistics
ExpirationVolumeOpen InterestImplied Volatility CallsImplied Volatility Puts
CallsPutsPut-Call RatioCallsPutsPut-Call RatioIVOiWaIvVWaIvIVOiWaIvVWaIv
2026-06-18 0.00 0 - - - - - -
2026-06-18 0.00 0 - - - - - -
2026-06-18 0.00 0 - - - - - -
Unlock Option Chain Statistics data
Real-Time ARQT Option Chain
CallsStrikePuts
Last PriceVolumeOpen InterestLast PriceVolumeOpen Interest
No data available
Unlock Option Chain data
Unlock Options Chart data
Open interest
0 600K 1.2M 1.8M Avg OI 1.00 M Open Interest
0 1 2 3 1.1 Put-Call Ratio
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
ARQT Option Volume & Put-Call Ratio
0 450K 900K 1.4M Avg OV 750.00 K Option Volume
0 1 2 3 0.95 Put-Call Ratio
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Latest Arcutis Biotherapeutics, Inc. (ARQT) News & Alerts
-
Thursday, June 11, 2026
(%)
+ More

Demo Biotech Announces Positive Phase 3 Results

Competitive Position
How ARQT ranks across every disease it competes in
Indication Rank Phase Best DrugTop 3 Competitors Market $B LoA Position
Vitiligo #6 of 8 PHASE 2 Roflumilast 0.3% foam
INCY PFE ABBV
$1.2B 0.85 FOLLOWER
Atopic Dermatitis #20 of 25 PHASE 1 ARQ-234
LLY ABBV PFE
$20.76B 0.99 FOLLOWER